Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 23-34

  Kimura, Tatsuo ^a   Kudoh, Shinzoh ^a   Hirata, Kazuto ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amrubicin; Amrubicinol; Refractory relapse; Second line chemotherapy; Sensitive relapse; Topoisomerase II inhibitor

Indexed keywords

AMRUBICIN; AMRUBICINOL; ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEFITINIB; GEMCITABINE; GYRASE INHIBITOR; IRINOTECAN; NAVELBINE; PLATINUM COMPLEX; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL FEATURE; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FATALITY; DRUG INTERACTION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; HYPONATREMIA; INFECTION; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; REVIEW; SEPTIC SHOCK; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 79958061953     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S5072     Document Type: Review

References (78)

1. Postmus PE, Smit EF. Treatment of relapsed small cell lung cancer. Semin Oncol. 2001;28:48-52.
2. Davies AM, Evans WK, Mackay JA, et al. Treatment of recurrent small cell lung cancer. Hematol Oncol Clin North Am. 2004;18:387-416.
3. Wolff SN, Birch R, Sarma P, et al. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986;70:583-7.
4. Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol. 1990;8:1613-7.
5. Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 1988;6:1264-70.
6. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1993;29A: 1720-2.
7. Furuse K, Kubota K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology. 1996;53:169-72.
8. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225-9.
9. Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77:347-51.
10. van der Lee I, Smit EF, van Putten JW, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol. 2001;12:557-61.
11. Hoang T, Kim K, Jaslowski A, et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer. 2003; 42:97-102.
12. Jalal S, Ansari R, Govindan R, et al. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol. 2009;4:93-6.
13. Gronberg BH, Bremnes RM, Aasebo U, et al. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer. 2009;63:88-93.
14. Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol. 2009;27:2046-51.
15. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15:2090-6.
16. Batist G, Carney DN, Cowan KH, et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol. 1986;4:982-6.
17. Sonpavde G, Ansari R, Walker P, et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol. 2000;23:68-70.
18. Kakolyris S, Mavroudis D, Tsavaris N, et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol. 2001;12:193-7.
19. Naka N, Kawahara M, Okishio K, et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer. 2002;37:319-23.
20. Ando M, Kobayashi K, Yoshimura A, et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer. 2004;44:121-7.
21. Masuda N, Matsui K, Negoro S, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1998;16:3329-34.
22. Rocha-Lima CM, Herndon JE 2nd, Lee ME, et al. Phase II trial of irinotecan/ gemcitabine as second-line therapy for relapsed and refractory smallcell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol. 2007;18:331-7.
23. Ardizzoni A, Manegold C, Debruyne C, et al. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res. 2003;9:143-50.
24. Shepherd FA, Evans WK, MacCormick R, et al. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep. 1987;71:941-4.
25. Faylona EA, Loehrer PJ, Ansari R, et al. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. J Clin Oncol. 1995;13: 1209-14.
26. Kosmas C, Tsavaris NB, Malamos NA, et al. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol. 2001;19:119-26.
27. Fennell DA, Steele JP, Shamash J, et al. Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer. Int J Cancer. 2007;121: 2575-7.
28. Kaira K, Sunaga N, Tomizawa Y, et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer. 2010;69:99-104.
29. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as secondline therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010;28:2598-603.
30. Weiss RB, Sarosy G, Clagett-Carr K, et al. Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol. 1986;18:185-97.
31. Yamaoka T, Hanada M, Ichii S, et al. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res. 1998;89:1067-73.
32. Kuffel MJ, Reid JM, Ames MM. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol. 1992;30: 51-7.
33. Morisada S, Yanagi Y, Noguchi T, et al. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res. 1989;80:69-76.
34. Suzuki T, Minamide S, Iwasaki T, et al. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs. 1997;15:219-25.
35. Noda T, Watanabe T, Kohda A, et al. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs. 1998;16:121-8.
36. Hanada M, Mizuno S, Fukushima A, et al. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res. 1998;89:1229-38.
37. Noguchi T, Ichii S, Morisada S, et al. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res. 1998;89:1061-6.
38. Noguchi T, Ichii S, Morisada S, et al. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res. 1998;89: 1055-60.
39. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapychemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979;5:85-91.
40. Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem. 1977;252: 6438-42.
41. Yamauchi S, Kudoh S, Kimura T, et al. Additive effects of amrubicin with cisplatin on human lung cancer cell lines. Osaka City Med J. 2002;48: 69-76.
42. Takagi T, Yazawa Y, Suzuki K, et al. Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines. Invest New Drugs. 1996;14:357-63.
43. Takigawa N, Ohnoshi T, Ueoka H, et al. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines. Acta Med Okayama. 1992;46:249-56.
44. Takigawa N, Takeyama M, Shibayama T, et al. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells. Oncol Rep. 2006;15:837-42.
45. Hanada M, Noguchi T, Yamaoka T. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo. Cancer Sci. 2007;98:447-54.
46. Wang JC. DNA topoisomerases. Annu Rev Biochem. 1985;54:665-97.
47. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta. 1989;989:163-77.
48. Gupta RS, Gupta R, Eng B, et al. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 1988;48:6404-10.
49. Kim R, Hirabayashi N, Nishiyama M, et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer. 1992;50:760-6.
50. Bertrand R, O'Connor PM, Kerrigan D, et al. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer. 1992;28A:743-8.
51. T. In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor. Osaka City Med J. 2001;47:33-41.
52. Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 1991;51:1129-36.
53. Goto K, Sekine I, Nishiwaki Y, et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer. 2004;91:659-65.
54. Quoix E, Breton JL, Gervais R, et al. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer. 2005;49:253-61.
55. Mok TS, Wong H, Zee B, et al. A phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer. 2002;95: 1511-9.
56. Okamoto I, Hamada A, Matsunaga Y, et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pharmacol. 2006;57:282-8.
57. Yanaihara T, Yokoba M, Onoda S, et al. Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2007;59:419-27.
58. Shibayama T, Hotta K, Takigawa N, et al. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Lung Cancer. 2006;53: 189-95.
59. Matsunaga Y, Hamada A, Okamoto I, et al. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. Ther Drug Monit. 2006;28:76-82.
60. Kimura T, Kudoh S, Mitsuoka S, et al. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities. Anticancer Drugs. 2009;20:513-8.
61. Inoue K, Ogawa M, Horikoshi N, et al. Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative. Invest New Drugs. 1989;7: 213-8.
62. Sugiura T, Ariyoshi Y, Negoro S, et al. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer. Invest New Drugs. 2005;23:331-7.
63. Igawa S, Yamamoto N, Ueda S, et al. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol. 2007;2:741-4.
64. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs. 2007; 25:253-8.
65. Kudoh S, Yoshimura N, Kimura T, et al. A phase II trial of amrubicin (AMR) for recurrent or refractory small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 2006;24:abstr 17053.
66. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24:5448-53.
67. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26:5401-6.
68. Kato T, Nokihara H, Ohe Y, et al. Phase II trial of amrubicin i patients with previously treated small cell lug cancer (SCLC). Proc Am Soc Clin Oncol. 2006;24:abstr 7061.
69. Jotte R, Conkling P, Reynolds C, et al. A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. J Clin Oncol. 2008;26:abstr 8040.
70. Inoue A, Yamazaki K, Maemondo M, et al. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer. J Thorac Oncol. 2006;1:551-5.
71. Hotta K, Takigawa N, Kiura K, et al. Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res. 2005;25:2429-34.
72. Oshita F, Saito H, Yamada K. Dose escalation study of amrubicin in combination with fixed-dose irinotecan in patients with extensive small-cell lung cancer. Oncology. 2008;74:7-11.
73. Nogami N, Kiura K, Takigawa N, et al. A phase II trial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC). J Clin Oncol. 2010;28 suppl:abstr 7054.
74. Yoshimura N, Kudoh S, Kimura T, et al. Phase I study of amrubicin and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2008;26 suppl:abstr 19119.
75. Ikeda J, Maruyama R, Okamoto T, et al. Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer. Jpn J Clin Oncol. 2006;36:12-6.
76. Ohe Y, Negoro S, Matsui K, et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol. 2005;16:430-6.
77. Fukuda M, Nakamura Y, Kasai T, et al. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. J Thorac Oncol. 2009;4:741-5.
78. Igawa S, Ryuge S, Fukui T, et al. Amrubicin for treating elderly and poorrisk patients with small-cell lung cancer. Int J Clin Oncol. 2010;15:447-52.